- Home
- NBTX vs MNMD Comparison
NBTX vs MNMD Comparison
Compare NBTX & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- MNMD
- Stock Information
- Founded
- NBTX 2003
- MNMD 2019
- Country
- NBTX France
- MNMD United States
- Employees
- NBTX N/A
- MNMD N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- MNMD Pharmaceuticals and Biotechnology
- Sector
- NBTX Health Care
- MNMD Health Care
- Exchange
- NBTX Nasdaq
- MNMD Nasdaq
- Market Cap
- NBTX 868.8M
- MNMD 811.9M
- IPO Year
- NBTX 2020
- MNMD N/A
- Fundamental
- Price
- NBTX $21.04
- MNMD $11.98
- Analyst Decision
- NBTX Strong Buy
- MNMD Strong Buy
- Analyst Count
- NBTX 1
- MNMD 6
- Target Price
- NBTX $8.00
- MNMD $26.50
- AVG Volume (30 Days)
- NBTX 112.7K
- MNMD 1.7M
- Earning Date
- NBTX 09-30-2025
- MNMD 11-06-2025
- Dividend Yield
- NBTX N/A
- MNMD N/A
- EPS Growth
- NBTX N/A
- MNMD N/A
- EPS
- NBTX N/A
- MNMD N/A
- Revenue
- NBTX $11,930,711.00
- MNMD N/A
- Revenue This Year
- NBTX N/A
- MNMD N/A
- Revenue Next Year
- NBTX $74.67
- MNMD N/A
- P/E Ratio
- NBTX N/A
- MNMD N/A
- Revenue Growth
- NBTX N/A
- MNMD N/A
- 52 Week Low
- NBTX $2.76
- MNMD $4.70
- 52 Week High
- NBTX $22.51
- MNMD $12.76
- Technical
- Relative Strength Index (RSI)
- NBTX 71.69
- MNMD 63.78
- Support Level
- NBTX $19.11
- MNMD $8.77
- Resistance Level
- NBTX $22.64
- MNMD $12.76
- Average True Range (ATR)
- NBTX 1.64
- MNMD 0.81
- MACD
- NBTX 0.63
- MNMD 0.21
- Stochastic Oscillator
- NBTX 83.03
- MNMD 78.18
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).